PC
Posner Christopher
Chairman & CEO
C-suiteM
€342,012
▼ Sales (14 ops.)
Insider track record
CEONot enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the detailed record of transactions filed by Posner Christopher, Chairman & CEO. Director active across 1 company, notably Cara Therapeutics, Inc.. Aggregated, 18 reports have been logged. Breakdown: 0 buy · 14 sells. Total volume traded: €342k. Activity tracked since 3 June 2021. The latest transaction was disclosed on 28 February 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Posner Christopher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
583 shares@ US$4.750.8% of flowCommon StockSEC:0001415889-25-006576:0
372 shares@ US$4.720.5% of flowCommon StockSEC:0001415889-25-003295:0
3,668 shares@ US$0.290.3% of flowCommon StockSEC:0001415889-24-026248:0
4,149 shares@ US$0.350.4% of flowCommon StockSEC:0001415889-24-020605:0
3,936 shares@ US$0.750.8% of flowCommon StockSEC:0001415889-24-012322:0
5,834 shares@ US$0.891.4% of flowCommon StockSEC:0001415889-24-006273:0
35,575 shares@ US$0.535.1% of flowCommon StockSEC:0001415889-24-003395:0
62,500 shares0Common StockSEC:0001415889-24-002513:0
3,796 shares@ US$1.221.3% of flowCommon StockSEC:0001209191-23-054332:0
4,307 shares@ US$3.073.5% of flowCommon StockSEC:0001209191-23-044636:0
3,869 shares@ US$4.404.5% of flowCommon StockSEC:0001209191-23-028247:0
5,987 shares@ US$9.7116.0% of flowCommon StockSEC:0001209191-23-016796:0
4,191 shares@ US$11.8013.1% of flowCommon StockSEC:0001209191-23-007170:0
14,470 shares@ US$11.1345.5% of flowCommon StockSEC:0001209191-22-057948:0
2,006 shares@ US$12.676.8% of flowCommon StockSEC:0001209191-22-023237:0
39,000 shares0Common StockSEC:0001209191-22-013988:0
5,941 shares0Common StockSEC:0001209191-21-062593:0
7,200 shares0Common StockSEC:0001209191-21-038764:0
About Posner Christopher
Posner Christopher is President and CEO of Cara Therapeutics, Inc. (XNAS). He has filed 18 disclosures in total, and across the 18 recent sampled filings from 2021-06-07 to 2025-03-04, the transactions are all sales, for a total amount of EUR 342012.